Cargando…
What is the status of immunotherapy in thyroid neoplasms?
Immunotherapy has changed the treatment of patients with advanced cancer, with different phase III trials showing durable responses across different histologies. This review focuses on the preclinical and clinical evidence of potential predictive biomarkers of response and efficacy of immunotherapy...
Autores principales: | Garcia-Alvarez, Alejandro, Hernando, Jorge, Carmona-Alonso, Ana, Capdevila, Jaume |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389039/ https://www.ncbi.nlm.nih.gov/pubmed/35992118 http://dx.doi.org/10.3389/fendo.2022.929091 |
Ejemplares similares
-
Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report
por: Mirallas, Oriol, et al.
Publicado: (2021) -
Proteotypic Differences of Follicular-Patterned Thyroid Neoplasms
por: Huang, Dongdong, et al.
Publicado: (2022) -
Immunohistochemistry in the pathologic diagnosis and management of thyroid neoplasms
por: Crescenzi, Anna, et al.
Publicado: (2023) -
Oncocytic Adrenocortical Neoplasm with Concomitant Papillary Thyroid Cancer
por: Podetta, Michele, et al.
Publicado: (2018) -
Genetics, Diagnosis, and Management of Hürthle Cell Thyroid Neoplasms
por: McFadden, David G., et al.
Publicado: (2021)